Ketoconazole has been widely used as an antifungal drug that is formulated as tablets, cream and overthecounter ketoconazole shampoo. The aim of this research was to study and to standardize an ultraviolet spectrophotometric (UVS) method, potentiometric and a high performance liquid chromatographic (HPLC) method for the determination of ketoconazole in commercially available Oromycosal® tablets. These three methods were compared and discussed with respect to their sensitivity, selectivity and readyapplicability in routine analytical work. Absorption spectra and spectrophotometric determinations were carried out on the UVS spectrophotometer. Investigated concentrations were in range from 0.003 to 0.02mg?dm3. The absorbance was measured at 224 nm. In potentiometric titrations glass and saturated (KCl) calomel electrode were used. HPLC analyses of ketoconazole were carried in the presence of econazole as internal standard. It can be concluded that the described methods are simple, fast and reliable for determination of ketoconazole in pharmaceutical preparations. The preparation of the samples is easy, the excipients do not interfere in the methods, so they can be used in routine quality control analysis., Biljana Gjorgjeska, and Literatura
Cíl: předvést praktické využití protokolu, který vydal v roce 2006 CLSI (Clinical and Laboratory Standards Institute) pod označením EP15-A2 Vol.25 No.17„User Verification of Performance for Precision and Trueness; Approved Guideline, Second Edition“ [1], dále jen EP15-A2, za účelem uživatelské verifikace preciznosti analytické metody deklarované výrobci IVD MD pro klinické laboratoře. Výsledky: verifikace preciznosti deklarovaná výrobcem se prováděla na koncentraci katalytické aktivity enzymu γ-glutamyltransferázy v lidském séru (měřená veličina), a měření se provádělo na dvou koncentračních hladinách vždy ve třech opakováních v průběhu pěti dní. Diskuse: upozornit na existenci potenciálního úskalí alternativního způsobu odhadu mezilehlé preciznosti měřicího postupu nazvaného „Varianta 1“ a uveřejněného v tomto časopise (dále jen KBM), č. 1/2011, ve sdělení českého kolektivu autorů „Doporučení k provádění validace a verifikace analytických metod v klinických laboratořích“ [2], dále jen „Doporučení“. Závěr: hodnocení čtyřkrokové aplikace protokolu EP15-A2 v praxi, přísliby nové verze EP15-A3, preciznost., Objective: to demonstrate the practical application of the EP15-A2 Vol. 25 No.17 CLSI document titled as „User Verification of Performance for Precision and Trueness; Approved Guideline, Second edition“ [1], next only EP15-A2, to the user verification („spot-checking“) analytical methods precision of manufacturer claims in clinical laboratories, which was published by CLSI 2006. Results: the precision manufacturer precision claims were tested on the gamma-glutamyltransferase catalytic concentration in human serum (measurand), at two levels, running 3 replicates on each of the 5 days. Discussion: the possible pitfalls of the analytical method precision alternative verification way when the intermediate precision is assessed as the „Option 1“ formerly published in „Recommendation to perform the analytical methods validation and verification in clinical laboratories“ [2], next only „Recommendation“, in this journal „Clinical biochemistry and metabolism“, next only KBM, No. 1/2011, by the Czech authors collective. Conclusion: the evaluation of 4-steps EP15-A2 protocol application in practice, the new version EP15-A3 promises., and Ambrožová J.